{'fraction_non_alphanumeric': 0.02753441802252816, 'fraction_numerical': 0.010012515644555695, 'mean_word_length': 5.722689075630252, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bilateral femoral capital avascular necrosis in a renal transplant recipient on tacrolimus-based immunosuppression.

Avascular osteonecrosis (AVN) of the femoral head is one of the most common skeletal complications of kidney transplantation [1,2]. Factors governing its prevalence, risk factors and therapy remain controversial, even four decades after the initial description. It is generally accepted that corticosteroids play a crucial role in the pathogenesis. Prevalence of this complication decreased following the introduction of cyclosporin [1,3], but the effect of more recently introduced immunosuppressive agents is not so well documented. Here we report a 22-year-old patient who developed bilateral femoral head AVN 3.5 months after kidney transplantation, despite being on tacrolimus.